LILLY FDA Approval NDA 021253

NDA 021253

LILLY

FDA Drug Application

Application #021253

Documents

Letter2006-02-22
Letter2006-09-18
Letter2006-02-22
Letter2005-09-15
Letter2006-03-01
Letter2006-12-28
Letter2008-08-19
Letter2009-11-19
Letter2010-02-01
Letter2010-06-03
Letter2010-12-06
Letter2014-12-23
Label2006-02-22
Label2006-08-29
Label2006-02-22
Label2006-02-28
Label2006-12-04
Label2009-09-17
Label2010-01-29
Label2010-06-03
Other Important Information from FDA2011-12-22
Letter2004-04-07
Letter2007-07-10
Letter2010-06-03
Label2004-04-05
Label2007-07-10
Label2010-06-03
Label2010-12-04
Label2015-01-09
Label2015-07-24
Review2005-07-13
Letter2016-10-14
Label2016-12-01
Label2017-02-27
Label2017-02-27
Letter2017-03-02
Letter2017-03-02
Label2018-03-28
Letter2018-03-29
Letter2019-10-23
Label2019-10-25
Medication Guide2019-10-25
Letter2020-04-22
Label2020-04-22
Medication Guide2020-04-22
Label2020-04-24
Medication Guide2020-04-24
Letter2020-04-24

Application Sponsors

NDA 021253LILLY

Marketing Status

Prescription001

Application Products

001INJECTABLE;INTRAMUSCULAR10MG/VIAL1ZYPREXAOLANZAPINE

FDA Submissions

TYPE 3; Type 3 - New Dosage FormORIG1AP2004-03-29STANDARD
LABELING; LabelingSUPPL4AP2006-02-16STANDARD
LABELING; LabelingSUPPL6AP2006-08-25STANDARD
LABELING; LabelingSUPPL12AP2006-02-16STANDARD
LABELING; LabelingSUPPL15AP2005-09-13STANDARD
LABELING; LabelingSUPPL16AP2006-02-23STANDARD
LABELING; LabelingSUPPL21AP2006-11-29STANDARD
LABELING; LabelingSUPPL26AP2007-07-06STANDARD
LABELING; LabelingSUPPL33AP2008-08-14STANDARD
LABELING; LabelingSUPPL36AP2009-08-31UNKNOWN
LABELING; LabelingSUPPL37AP2010-01-27UNKNOWN
LABELING; LabelingSUPPL39AP2010-05-27UNKNOWN
LABELING; LabelingSUPPL43AP2010-05-27UNKNOWN
MANUF (CMC); Manufacturing (CMC)SUPPL44AP2014-09-30STANDARD
LABELING; LabelingSUPPL45AP2010-12-01901 REQUIRED
LABELING; LabelingSUPPL48AP2014-12-19STANDARD
LABELING; LabelingSUPPL49AP2015-07-23STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL52AP2014-08-11STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL55AP2016-10-27N/A
LABELING; LabelingSUPPL56AP2016-10-06901 REQUIRED
LABELING; LabelingSUPPL57AP2017-02-23STANDARD
LABELING; LabelingSUPPL58AP2017-02-23901 REQUIRED
LABELING; LabelingSUPPL59AP2018-03-27STANDARD
LABELING; LabelingSUPPL60AP2019-10-22STANDARD
LABELING; LabelingSUPPL61AP2020-04-23STANDARD
LABELING; LabelingSUPPL62AP2020-04-21901 REQUIRED

Submissions Property Types

SUPPL26Null4
SUPPL36Null7
SUPPL37Null7
SUPPL39Null7
SUPPL43Null6
SUPPL44Null0
SUPPL45Null6
SUPPL48Null7
SUPPL49Null15
SUPPL52Null0
SUPPL56Null6
SUPPL57Null6
SUPPL58Null7
SUPPL59Null15
SUPPL60Null6
SUPPL61Null6
SUPPL62Null6

TE Codes

001PrescriptionAP

CDER Filings

cder:Array
(
    [0] => Array
        (
            [ApplNo] => 21253
            [companyName] => 
            [docInserts] => ["",""]
            [products] => []
            [labels] => 
            [originalApprovals] => []
            [supplements] => 
            [actionDate] => 0000-00-00
        )

)

© 2026 FDA.report
This site is not affiliated with or endorsed by the FDA.